INAB

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of Inb-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

时间:2024-12-10 20:00:01 市场: 美股 综合

关联: INAB

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of Inb-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (Sno) Annual Meeting

时间:2024-11-25 20:00:00 市场: 综合 美股

关联: INAB

IN8bio Q3 Operating Income USD -7.086 Million

时间:2024-11-13 05:26:01 市场: 美股 综合

关联: INAB

IN8bio Q3 Basic EPS USD -0.15

时间:2024-11-13 05:26:01 市场: 美股 综合

关联: INAB

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

时间:2024-11-13 05:26:01 市场: 美股 综合

关联: INAB

Aigh Capital Management, Llc Reports 9.3% Passive Stake in IN8bio, Inc. as of Oct 1

时间:2024-10-10 05:21:57 市场: 美股 综合

关联: INAB

IN8bio Announces Pricing of $12.4 Million Private Placement

时间:2024-10-01 20:00:00 市场: 美股 综合

关联: INAB